4.4 Article

Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

Journal

TRIALS
Volume 22, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13063-021-05027-9

Keywords

Pneumonia; ACE2; Bradykinin; Icatibant; C1 esterase inhibitor

Funding

  1. Emergency project-Rapid Implementation of Supplements Against COVID-19 of the Sao Paulo Research Foundation [FAPESP 2020/04522-5]
  2. Research, Innovation and Dissemination Center -Obesity and Comorbidities Research Center of the Sao Paulo Research Foundation [FAPESP 2013/07607-8]
  3. University of Campinas, Campinas, Sao Paulo, Brazil

Ask authors/readers for more resources

This study aims to explore the mechanism of increased bradykinin in the lungs of COVID-19 patients in developing pneumonia and respiratory failure, with three arms of randomized clinical trial designed for different treatment regimens. The results of the study may help alleviate lung inflammatory response in severe COVID-19 patients, positively impacting disease severity and mortality rates.
Background: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradykinin, a potent inflammatory substance. We hypothesize that increased bradykinin in the lungs is an important mechanism driving the development of pneumonia and respiratory failure in COVID-19. Methods: This is a phase II, single-center, three-armed parallel-group, open-label, active control superiority randomized clinical trial. One hundred eighty eligible patients will be randomly assigned in a 1:1:1 ratio to receive either the inhibitor of C1e/kallikrein 20 U/kg intravenously on day 1 and day 4 plus standard care; or icatibant 30 mg subcutaneously, three doses/day for 4 days plus standard care; or standard care alone, as recommended in the clinical trials published to date, which includes supplemental oxygen, non-invasive and invasive ventilation, antibiotic agents, anti-inflammatory agents, prophylactic antithrombotic therapy, vasopressor support, and renal replacement therapy. Discussion: Accumulation of bradykinin in the lungs is a common side effect of ACE inhibitors leading to cough. In animal models, the inactivation of ACE2 leads to severe acute pneumonitis in response to lipopolysaccharide (LPS), and the inhibition of bradykinin almost completely restores the lung structure. We believe that inhibition of bradykinin in severe COVID-19 patients could reduce the lung inflammatory response, impacting positively on the severity of disease and mortality rates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available